Trial reportPloS one2013
454 pyrosequencing analysis on faecal samples from a randomized DBPC trial of colicky infants treated with Lactobacillus reuteri DSM 17938.
Trial report in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00893711 (Lactobacillus Reuteri Versus Placebo in the Treatment and Prevention of Infantile Colic), which is not on this map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Lactobacillus Reuteri Versus Placebo in the Treatment and Prevention of Infantile Colic: a Clinical and Microbiological, Double-blind, Prospective, Randomised, Controlled Study
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Faecal Microbiota in Infants and Young Children with Functional Gastrointestinal Disorders: A Systematic Review.Nutrients · 2022Pooled it
- Pooled it
- Gut microbiota is associated with adiposity markers and probiotics may impact specific genera.European journal of nutrition · 2020Trial
- Neonatal diet alters fecal microbiota and metabolome profiles at different ages in infants fed breast milk or formula.The American journal of clinical nutrition · 2020Trial
- Trial
- Lactobacillus reuteri for Infants with Colic: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.The Journal of pediatrics · 2017Trial
- Impact of Lactobacillus reuteri colonization on gut microbiota, inflammation, and crying time in infant colic.Scientific reports · 2017Trial
- Trial
- Associations of cord blood biomarkers with infant colic and excessive crying.Frontiers in pediatrics · 2026Article
- Probiotics in Functional Gastrointestinal Disorders.Advances in experimental medicine and biology · 2024Review
- Non-inhibitory levels of oxygen during cultivation increase freeze-drying stress tolerance inFrontiers in microbiology · 2023Article
- The role of potential probiotic strainsFrontiers in microbiology · 2023Review
- Probiotics added to maternal nutrition affect ınfantile colic symptoms and fecal microbiota profile: a single-blind randomized controlled study.Clinical and experimental pediatrics · 2022Article
- Probiotics and Functional Gastrointestinal Disorders in Pediatric Age: A Narrative Review.Frontiers in pediatrics · 2022Review
- Impact of Helicobacter pylori eradication on the gastric microbiome.Gut pathogens · 2021Article
- Metagenomic and metatranscriptomic profiling of Lactobacillus casei Zhang in the human gut.NPJ biofilms and microbiomes · 2021Article
- Colonization of SupplementedFrontiers in microbiology · 2021Article
- Microbiome of the first stool after birth and infantile colic.Pediatric research · 2020Article
- The food-gut axis: lactic acid bacteria and their link to food, the gut microbiome and human health.FEMS microbiology reviews · 2020Review
- Different Effects of Soil Fertilization on Bacterial Community Composition in theApplied and environmental microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the global microbial composition, using large-scale DNA sequencing of 16 S rRNA genes, in faecal samples from colicky infants given L. reuteri DSM 17938 or placebo.
methodsTwenty-nine colicky infants (age 10-60 days) were enrolled and randomly assigned to receive either Lactobacillus reuteri (10(8) cfu) or a placebo once daily for 21 days. Responders were defined as subjects with a decrease of 50% in daily crying time at day 21 compared with the starting point. The microbiota of faecal samples from day 1 and 21 were analyzed using 454 pyrosequencing. The primers: Bakt_341F and Bakt_805R, complemented with 454 adapters and sample specific barcodes were used for PCR amplification of the 16 S rRNA genes. The structure of the data was explored by using permutational multivariate analysis of variance and effects of different variables were visualized with ordination analysis.
resultsThe infants' faecal microbiota were composed of Proteobacteria, Firmicutes, Actinobacteria and Bacteroidetes as the four main phyla. The composition of the microbiota in infants with colic had very high inter-individual variability with Firmicutes/Bacteroidetes ratios varying from 4000 to 0.025. On an individual basis, the microbiota was, however, relatively stable over time. Treatment with L. reuteri DSM 17938 did not change the global composition of the microbiota, but when comparing responders with non-responders the group responders had an increased relative abundance of the phyla Bacteroidetes and genus Bacteroides at day 21 compared with day 0. Furthermore, the phyla composition of the infants at day 21 could be divided into three enterotype groups, dominated by Firmicutes, Bacteroidetes, and Actinobacteria, respectively.
conclusionL. reuteri DSM 17938 did not affect the global composition of the microbiota. However, the increase of Bacteroidetes in the responder infants indicated that a decrease in colicky symptoms was linked to changes of the microbiota.
trial registrationClinicalTrials.gov NCT00893711.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.